Skip to main content

Advertisement

SpringerLink
Log in

The Role of Genomics in the Management of Advanced Bladder Cancer

  • Genitourinary Cancers (W Oh and M Galsky, Section Editors)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Advanced bladder cancer (ABC) is an aggressive malignancy with a poor prognosis. For the last 30 years, the standard of care for this disease has consisted of combination chemotherapy with a platinum-containing regimen as first-line therapy. Cisplatin is the most active cytotoxic agent against bladder cancer, but because of competing comorbidities, many patients are ineligible for this agent and instead receive carboplatin. The two-drug regimen of cisplatin and gemcitabine was found to be better tolerated and have comparable efficacy as the four-drug regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in a randomized study of patients with advanced disease. Therefore, cisplatin (or carboplatin) and gemcitabine is the most commonly used first-line regimen in this setting. No agents have been approved by the Food and Drug Administration (FDA) for second-line therapy in ABC. If patients are eligible for additional systemic treatment at the time of progression, options include single-agent therapy such as a taxane or pemetrexed, though given the lack of standard approaches participation in a clinical trial should be strongly encouraged. Recent molecular characterization of ABC reveals significant genetic heterogeneity and actionable genomic alterations in the majority of tumors. Emerging therapies may effectively target known molecular drivers of ABC, including the FGFR2, EGFR/HER2, VEGF, MET, and PI3/AKT/mTOR pathways. Reports of dramatic and prolonged responses to targeted therapy provide additional support for the use of genome sequencing in the rationale selection of treatment for subsets of patients. The current focus of clinical trial development is to design molecularly driven studies that “match” tumors with driver mutations and appropriate targeted therapies rather than a “one-size-fits-all” approach based on clinical and pathologic parameters of disease. The hope of patients and clinicians alike is that this therapeutic approach combined with novel agents may usher in a new era of effective treatments for patients with ABC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.

    PubMed  Google Scholar 

  2. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol. 2006;24:5519–27.

    Article  PubMed  Google Scholar 

  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  4. Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37:219–25.

    Article  PubMed  Google Scholar 

  5. Ortmann CA, Mazhar D. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol. 2013;9:1637–51.

    Article  CAS  PubMed  Google Scholar 

  6. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406–10.

    Article  CAS  PubMed  Google Scholar 

  7. Morales-Barrera R, Suarez C, Valverde C, et al. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clin Transl Oncol. 2014;16:102–6.

    Article  CAS  PubMed  Google Scholar 

  8. Morrison CD, Liu P, Woloszynska-Read A, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014;111:E672–81. This report describes the complete genome analysis of five muscle-invasive bladder cancers and reports findings of chromothripsis secondary to nonhomologous end-joining.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–65. This article characterizes intrinsic subtypes of bladder cancer and discusses potential genomic explanations for differential chemosensitivity between groups.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111:3110–5. This report highlights similarities between the intrinsic subtypes of bladder cancer independently identified by this group and well-established subtypes of breast cancer.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22. This study is an integrated genomic analysis that comprehensively catalogs alterations in bladder cancer, including mutations not previously identified in cancer.

    Article  Google Scholar 

  12. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133–40. This integrative analysis revealed actionable genomic alterations in the majority of high-grade bladder tumors studied.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2013;27:271–80. This comprehensive next-generation sequencing study of 35 metastatic bladder cancers reports the prevalence of genomic alterations.

  14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713–25.

    Article  CAS  PubMed  Google Scholar 

  15. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol. 2012;30:647–60. This timely review provides an introduction to the rapidly developing field of genomics as applied to oncology.

    Article  PubMed  Google Scholar 

  16. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221. This report was the first to identify an underlying molecular mechanism for response to a targeted agent in bladder cancer based on genomic sequencing.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546–53. Similar to the report by Iyer at al., this paper describes molecular mechanisms for sensitivity to everolimus and pazopanib in one patient with bladder cancer.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112:462–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400–10. This is an excellent review that summarizes the current understanding of molecular subtypes of bladder cancer and draws parallels with breast cancer subtypes.

    Article  CAS  PubMed  Google Scholar 

  20. US Na. Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients with Bladder Cancer. June 2014. Accessed 23 Jul 2013.

  21. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007;104:13086–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43:875–8.

    Article  CAS  PubMed  Google Scholar 

  23. Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45:1459–63.

    Article  CAS  PubMed  Google Scholar 

  24. Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013;45:1428–30.

    Article  CAS  PubMed  Google Scholar 

  25. Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet. 2014;23:1964–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45:1464–9.

    Article  CAS  PubMed  Google Scholar 

  27. Sapre N, Herle P, Anderson PD, Corcoran NM, Hovens CM. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology. 2014;46:274–82. This is a thorough review of the development of prognostic genetic and epigenetic molecular biomarkers for bladder cancer, including non-muscle invasive disease.

    Article  CAS  PubMed  Google Scholar 

  28. Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer. Curr Opin Urol. 2013;23:472–8. This review provides a concise discussion of known actionable mutations and therapeutic implications for muscle-invasive bladder cancer.

    Article  PubMed  Google Scholar 

  29. Riester M, Taylor J, Feifer A, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18:1323–33.

  30. Kim WJ, Kim SK, Jeong P, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17:478–85.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Kim WT, Kim J, Yan C, et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol. 2014;25:974–9.

    Article  CAS  PubMed  Google Scholar 

  32. Gallagher DJ, Vijai J, Hamilton RJ, et al. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Ann Oncol. 2013;24:2414–21.

    Article  CAS  PubMed  Google Scholar 

  33. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, et al. MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 2012;5:40. 8794–5–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Yu HJ, Chang YH, Pan CC. Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder. Histopathology 2012;62:788–98.

  35. Acquaviva J, He S, Zhang C, et al. FGFR3 Translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res. 2014;12:1042–54.

    Article  CAS  PubMed  Google Scholar 

  36. Acquaviva J, He S, Sang J, et al. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Mol Cancer Res. 2014;12:703–13.

    Article  CAS  PubMed  Google Scholar 

  37. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;202. 5; discussion 205–6. This meta-analysis reports the overall survival benefit of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

  38. Patafio FM, Mackillop WJ, Feldman-Stewart D, Siemens DR, Booth CM. Why is perioperative chemotherapy for bladder cancer underutilized? Urol Oncol. 2014;32:391–5.

    Article  PubMed  Google Scholar 

  39. Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer. 2014;120:1630–8.

    Article  PubMed  Google Scholar 

  40. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.

    Article  PubMed  Google Scholar 

  41. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32:1895–901.

    Article  CAS  PubMed  Google Scholar 

  42. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32:1889–94.

    Article  CAS  PubMed  Google Scholar 

  43. Sternberg CN, Skoneczna IA, Kerst JM, et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol. 2014;32(Suppl):abstr 4500. This abstract provides the most recent data on the potential benefit of adjuvant chemotherapy in muscle-invasive bladder cancer following cystectomy.

  44. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506–13.

    Article  CAS  PubMed  Google Scholar 

  45. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432–8. This commentary provides recommendations for the management of patients with metastatic bladder cancer who are ineligible for cisplatin-chemotherapy based on expert consensus.

    Article  PubMed  Google Scholar 

  46. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.

    Article  CAS  PubMed  Google Scholar 

  47. Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer (Version 2.2014). J Natl Compr Cancer Netw. 2014;2014:446–75.

    Google Scholar 

  48. Guancial EA, Werner L, Bellmunt J, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014;3(4):835–44.

  49. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795–803.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Milowsky MI, Dittrich C, Martinez ID, et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol. 2013;(Suppl 6):abst 255.

  51. US National Library of Medicine. Phase 1b Trial of BGJ398/BYL719 in Solid Tumors February 2014. Accessed 5 Jul 2014.

  52. US National Library of Medicine. BGJ398 for Patients with Tumors with FGFR Genetic Alterations July 2014. Accessed 13 Jul 2014.

  53. US National Library of Medicine. A Dose Escalation Study in Adult Patients with Advanced Solid Malignancies July 2014. Accessed 15 Jul 2014.

  54. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol. 2012;43:1590–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26:305–20. This is a comprehensive update of completed and ongoing clinical trials of targeted therapy in non-muscle invasive and muscle invasive bladder cancer.

    Article  CAS  PubMed  Google Scholar 

  56. US National Library of Medicine. PURO Panitumumab in Combination with Gemcitabine/Cisplatin in Advanced Urothelial Cancer March 2014. Accessed 5 Jul 2014.

  57. US National Library of Medicine. Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer May 2013. Accessed 1 Oct 2014.

  58. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7.

    Article  CAS  PubMed  Google Scholar 

  59. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218–24.

    Article  CAS  PubMed  Google Scholar 

  60. US National Library of Medicine. Lapatininb, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer June 2014. Accessed 5 Jul 2014.

  61. US National Library of Medicine. Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma of the Bladder February 2014. Accsssed 15 Jul 2014.

  62. US National Library of Medicine. A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium (LaMB) July 2014. Accessed 15 Jul 2014.

  63. US National Library of Medicine. Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing April 2013. Accessed 15 Jul 2014.

  64. Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33:2381–90.

    CAS  PubMed  Google Scholar 

  65. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009;27:391–9.

    Article  CAS  PubMed  Google Scholar 

  66. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525–30.

    Article  CAS  PubMed  Google Scholar 

  67. Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31:724–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. US National Library of Medicine. Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients with Advanced Urinary Tract Cancer June 2014. Accessed 15 Jul 2014.

  69. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO Meet Abstr. 2008;26:291.

    Google Scholar 

  70. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2010;29:1045–9.

  71. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115:4090–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28:1373–9.

    Article  CAS  PubMed  Google Scholar 

  73. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013;11:175–81.

    Article  PubMed  Google Scholar 

  74. Krege S, Rexer H, vom Dorp F, et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int. 2014;113:429–36.

    Article  CAS  PubMed  Google Scholar 

  75. US National Library of Medicine. Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients with Advanced/Metastatic Bladder Carcinoma June 2014. Accessed 15 Jul 2014.

  76. US National Library of Medicine. Phase I Study with Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR) April 2013. Accessed 5 Jul 2014.

  77. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810–6.

    Article  CAS  PubMed  Google Scholar 

  78. Pili R, Qin R, Flynn PJ, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11:477–83.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs. 2013;24:422–5.

    Article  CAS  PubMed  Google Scholar 

  80. US National Library of Medicine. Gemcitabine and Pazopanib in Chemotherapy Naive Patients with Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy February 2014. Accessed 5 Jul 2014.

  81. US National Library of Medicine. Phase II Pazopanib in Combination with Weekly Paclitaxel in Refractory Urothelial Cancer July 2014. Accessed 15 Jul 2014.

  82. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:553–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. US National Library of Medicine. Cabozantinib for Advanced Urothelial Cancer June 2014; July 5, 2014.

  84. Bellmunt J, Teh BT, Tortora G, Rosenberg JE. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013;10:557–70. This recent review focuses on the use of whole-genome sequencing in the identification of therapeutic targets in non-hormonally driven urothelial cancers, including bladder cancer.

    Article  CAS  PubMed  Google Scholar 

  85. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23:2663–70.

    Article  CAS  PubMed  Google Scholar 

  86. US National Library of Medicine. Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients with Advanced Solid Tumor Malignancies April 2014. Accessed 5 Jul 2014.

  87. US National Library of Medicine. First-line Everolimus ± Paclitaxel for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma April 2014. Accessed 5 Jul 2014.

  88. US National Library of Medicine. Gemcitabine Hydrocholoride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients with Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium August 2013. Accessed 15 Jul 2014.

  89. US National Library of Medicine. Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients with Advanced Bladder Cancer (VESTOR) April 2013. Accessed 5 Jul 2014.

  90. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282–90.

    Article  CAS  PubMed  Google Scholar 

  91. US National Library of Medicine. Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium July 2014. Accessed 15 Jul 2014.

  92. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther. 2007;6:299–308.

    Article  CAS  PubMed  Google Scholar 

  93. Garg M, Kanojia D, Seth A, et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer. 2010;46:207–15.

    Article  CAS  PubMed  Google Scholar 

  94. US National Library of Medicine. A Phase 2 Study Comparing Chemotherapy in Combination with OGX-427 or Placebo in Patients with Bladder Cancer July 2013. Accessed 5 Jul 2014.

  95. US National Library of Medicine. Phase 2 Study of Docetaxel ± OGX-427 in Patient with Relapsed or Refractory Metastatic Bladder Cancer June 2014. Accessed 15 Jul 2014.

Download references

Compliance with Ethics Guidelines

Conflict of Interest Elizabeth A. Guancial and Jonathan E. Rosenberg declare that they have no conflict of interest

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA

    Elizabeth A. Guancial MD

  2. Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA

    Jonathan E. Rosenberg MD

Authors
  1. Elizabeth A. Guancial MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan E. Rosenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth A. Guancial MD.

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guancial, E.A., Rosenberg, J.E. The Role of Genomics in the Management of Advanced Bladder Cancer. Curr. Treat. Options in Oncol. 16, 4 (2015). https://doi.org/10.1007/s11864-014-0319-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-014-0319-z

Keywords

Search

Navigation